Physician profile
Stephen Vaccarezza
NPI 1861488314
$4,738.31
in general payments reported to CMS, 2019-2025
24 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $243 · 2021: $853 · 2022: $912 · 2023: $729 · 2024: $909 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233 · Education: $42.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,232.85 |
| Education | $42.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,344.32 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $630.26 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $363.46 | 2021-2025 | Tavneos, Aranesp, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $360.43 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $320.75 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $261.04 | 2020-2022 | |
| Travere Therapeutics, INC. | $240.36 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $227.65 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $222.13 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $169.65 | 2022-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $136.93 | 2019-2024 | Velphoro |
| Opko Pharmaceuticals, LLC | $120.04 | 2021-2023 | Rayaldee |
| Akebia Therapeutics INC | $59.00 | 2022-2024 | Auryxia |
| Novo Nordisk INC | $47.44 | 2025 | Ozempic |
| Genzyme Corporation | $43.48 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $30.94 | 2020-2024 | Crysvita |
| Mallinckrodt Enterprises LLC | $27.03 | 2019 | |
| Lilly USA, LLC | $24.43 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $23.97 | 2023 | Benlysta |
| Horizon Therapeutics Plc | $20.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.22 | 2024 | Jardiance |
| Ani Pharmaceuticals, INC. | $18.35 | 2024 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.58 | 2019 | |
| Nxstage Medical, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Vaccarezza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.